Literature DB >> 29366380

Oral solution of fructose promotes SREBP-1c high-expression in the hypothalamus of Wistar rats.

Leandro Oliveira Batista1,2, Viviane Wagner Ramos1,2, Mariana Alejandra Rosas Fernández1,3, Carlos Marcelo Concha Vilca1,2, Kelse Tibau de Albuquerque1,2,3.   

Abstract

Objective: We evaluate whether the consumption of fructose for 8 weeks affects enzymes and transcription factors of the lipogenic and inflammatory pathways in the hypothalamus of Wistar rats.
Methods: At 30 days, the animals were divided into groups: Control (C) and Fructose (F) and maintained with free access to feed and filtered water (C) or aqueous solution of purified fructose at 20% (F). RT-PCR and Western blotting were performed for the target genes and proteins.
Results: In F group, results showed a lower feed intake, an increase in glycemia (146.20 ± 6.09 vs. 102.32 ± 4.58; n: 9) and triacylglycerol (F: 191.65 ± 13.51 vs. C: 131.69 ± 6.49; n: 9) and there was no difference in water and energy consumption. We identified a higher content of acetyl-CoA carboxylase (ACC) (F: 133.93 ± 5.58 vs. C: 100 ± 0.0; n: 9-10) and NFκB (F: 125.5 ± 8.85 vs. C: 100 ± 0; n: 14) in group F, whereas fatty acid synthase (FAS) was lower (F: 85.90 ± 4.81 vs. C: 100 ± 0.0; n: 4-6). SREBP-1c gene expression was higher in F vs. C group (F: 4.08 ± 0.44 vs. C: 1.13 ± 0.15; n: 5-6), although we did not found difference between groups in the gene expression for ACC, SREBP-2, and NFκB. Discussion: Dietary fructose can change important lipogenic and inflammatory factors in the hypothalamus of rats and it leads to regulation of transcription factors before changes in body mass are evident.

Entities:  

Keywords:  Central control of food intake; Fructose; Hypothalamus; Inflammation; Lipogenesis

Mesh:

Substances:

Year:  2018        PMID: 29366380     DOI: 10.1080/1028415X.2018.1427659

Source DB:  PubMed          Journal:  Nutr Neurosci        ISSN: 1028-415X            Impact factor:   4.994


  1 in total

1.  Pueraria lobata root polysaccharide alleviates glucose and lipid metabolic dysfunction in diabetic db/db mice.

Authors:  Dan Luo; Xiaokang Dong; Jie Huang; Chengcheng Huang; Guowei Fang; Yanqin Huang
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.